Chai Discovery Closes $400M Series C: Chai-3 Doubles Antibody Design Success Rate, Eli Lilly, Pfizer, and Novartis Back AI Drug Discovery Star

Introduction

In July 2026, San Francisco AI drug discovery startup Chai Discovery closed a $400 million Series C funding round, achieving a valuation of $3.8 billion — just seven months earlier, its Series B valuation was $1.3 billion, representing nearly a three-fold increase. Behind this remarkable growth rate are breakthrough advances by the Chai-3 model in antibody design and strategic bets from global pharmaceutical giants including Eli Lilly, Pfizer, and Novartis.

Company Positioning: AI Pharma Infrastructure Provider

Chai Discovery's business model differs fundamentally from competitors like Isomorphic Labs and Recursion Pharmaceuticals: it maintains no wet labs and owns no proprietary drug candidates, instead positioning itself as a pure-play software infrastructure provider that licenses its AI models to pharmaceutical companies.

This "picks and shovels" strategy enables Chai Discovery to:

• Avoid high laboratory operating costs
• Rapidly scale to multiple pharmaceutical partners
• Focus on continuous model capability improvements
• Share in industry growth without bearing drug development risks

Chai-3: Technical Breakthrough in Zero-Shot Antibody Design

Three Generations of Model Evolution

Chai Discovery's technical development has progressed through three key phases:

Chai-1 (2024): An open-source foundational model focused on molecular structure prediction, establishing the company's technical reputation.

Chai-2 (2025): A zero-shot generative platform for de novo antibody design, achieving 16-20% experimental hit rates — more than 100 times the improvement over traditional computational methods (typically below 0.1%).

Chai-3 (2026): The current latest generation, building on Chai-2 to reduce antibody design failure rates by approximately 50%, doubling hit rates again. More importantly, Chai-3 can complete the full cycle from computational design to wet-lab validation in just two weeks.

The Revolutionary Significance of Zero-Shot Design

Traditional antibody development relies on extensive experimental screening, typically requiring months or even years and costing tens of millions of dollars. Chai-3's "zero-shot" design capability means:

• No target-specific training data required: Directly generating functional antibody sequences from target antigens and epitopes
• Multi-specific molecule engineering: Designing complex antibodies that simultaneously target multiple targets
• Tackling "hard-to-drug" targets: Providing solutions for targets that traditional methods struggle to address
• Two-week validation cycle: Only two weeks from computational design to wet-lab validation

Strategic Partnerships with Top Pharmaceutical Companies

Eli Lilly

Partnership announced in January 2026, leveraging Chai's models to design multiple novel biologics. This was Chai Discovery's first major collaboration with a global top-tier pharmaceutical company, validating the commercial viability of its technology.

Pfizer

A landmark licensing agreement announced in June 2026, granting Pfizer early access to the Chai-3 model. The agreement's unique feature is the inclusion of custom AI model development: training proprietary models on Pfizer's proprietary datasets, allowing Pfizer to integrate Chai's generative engine directly into its internal R&D workflows.

Novartis

Partnership announced in July 2026, further solidifying Chai Discovery's position among global top-tier pharmaceutical companies.

argenx

Also announced in July 2026, argenx is a biotechnology company focused on immunology, and its collaboration further validates Chai-3's application value in specific therapeutic areas.

Funding Details and Investor Lineup

The Series C was led by Index Ventures, with participation from:

• Established VCs: Kleiner Perkins, Sequoia Capital, Dimension
• New investors: Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital
• Strategic investors: OpenAI, Thrive Capital, General Catalyst

Since its founding in 2024, Chai Discovery has raised approximately $630 million across four funding rounds. Valuation surged from $1.3 billion at Series B (December 2025) to $3.8 billion at Series C (July 2026), nearly tripling in seven months, primarily attributed to successful commercial partnerships with top pharmaceutical companies.

Macro Context of the AI Drug Discovery Industry

Chai Discovery's rise occurs during an overall explosion in the AI drug discovery industry:

• Market size: The AI-driven pharmaceutical research market is projected to reach $28.6 billion by 2034
• Industry investment: Digital health venture capital reached $4 billion in Q1 2026
• Competitive landscape: Competitors including Isomorphic Labs (DeepMind subsidiary) and Recursion Pharmaceuticals are also rapidly developing
• Regulatory environment: The FDA continues to refine its approval framework for AI-assisted drug discovery

Chai Discovery's "pure-play software infrastructure" positioning gives it a unique competitive advantage: it doesn't compete with pharmaceutical companies but becomes their technology enabler.

Impact on Asia-Pacific

Japanese Pharmaceutical Industry

Japan is the world's third-largest pharmaceutical market, with companies like Takeda and Astellas actively exploring AI drug discovery partnerships. Chai Discovery's successful model provides an important reference for Japanese pharmaceutical companies.

Chinese Biotechnology

China's biotechnology industry is rapidly rising, with companies like BeiGene and Innovent Biologics holding important positions in the antibody drug field. Chai-3's technical breakthroughs will accelerate Chinese pharmaceutical companies' evaluation of AI antibody design tools.

Singapore and Australia

Both have active biotechnology ecosystems. Chai Discovery's open-source Chai-1 model is already widely used in academia, laying the foundation for future commercial partnerships.

Challenges and Risks

Despite the bright prospects, Chai Discovery still faces several challenges:

Validation Risk: While the 16-20% hit rate far exceeds traditional methods, it still means most designs require further optimization. As the industry moves toward large-scale clinical trials, these performance claims require more rigorous real-world validation.

Competitive Pressure: The AI drug discovery field is highly competitive, with well-funded competitors rapidly catching up.

Regulatory Uncertainty: Drugs designed with AI assistance still face uncertainty in regulatory approval, with different regulatory agencies having varying attitudes and requirements.

Conclusion

Chai Discovery's $400 million Series C and $3.8 billion valuation represent not just recognition of its technical capabilities, but an important signal that the entire AI drug discovery industry is entering maturity. Chai-3's ability to double antibody design success rates and complete validation cycles in two weeks is fundamentally changing the speed and cost structure of drug discovery.

For Asia-Pacific pharmaceutical companies and biotechnology investors, Chai Discovery's rise provides an important insight: competitive advantage in AI drug discovery lies not in having the largest laboratory, but in mastering the most advanced AI models and the broadest pharmaceutical partnership network.